A novel epigenetic phenotype associated with the most aggressive pathway of bladder tumor progression

Journal of the National Cancer Institute

Volumn 103, Issue 1, 2011, Pages 47-60

  Vallot, Céline ^a,b   Stransky, Nicolas ^a,b,j   Bernard Pierrot, Isabelle ^a,b   Hérault, Aurélie ^a,b   Zucman Rossi, Jessica ^c   Chapeaublanc, Elodie ^a,b   Vordos, Dimitri ^d,e   Laplanche, Agns ^f   Benhamou, Simone ^f   Lebret, Thierry ^g   Southgate, Jennifer ^h,i   Allory, Yves ^d,f   Radvanyi, Franois ^a,b  

^a INSTITUT CURIE   (France)

^b INSTITUT CURIE   (France)

^c Université Paris 13   (France)

^d INSERM U955   (France)

^e FACULTÉ DE MÉDECINE   (France)

^f HENRI MONDOR HOSPITAL   (France)

^g INSTITUT GUSTAVE ROUSSY   (France)

^h FOCH HOSPITAL   (France)

ⁱ UNIVERSITY OF YORK   (United Kingdom)

^j BROAD INSTITUTE OF MIT AND HARVARD   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; BISULFITE; FIBROBLAST GROWTH FACTOR RECEPTOR 3; HISTONE H3; TRICHOSTATIN A;

ADULT; AGED; ARTICLE; BLADDER CANCER; BLADDER TUMOR; CANCER CELL CULTURE; CANCER GRADING; CANCER STAGING; CARCINOGENESIS; CARCINOMA IN SITU; CHROMATIN IMMUNOPRECIPITATION; CHROMOSOME; COMPARATIVE STUDY; CONTROLLED STUDY; DNA METHYLATION; EPIGENETICS; FEMALE; GENE CLUSTER; GENE EXPRESSION; GENE MUTATION; GENE SILENCING; GENETIC ASSOCIATION; HISTONE ACETYLATION; HISTONE METHYLATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; MUSCLE TUMOR; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; REAL TIME POLYMERASE CHAIN REACTION; RNA ANALYSIS; TUMOR CELL LINE; TUMOR GROWTH; UROTHELIUM;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA IN SITU; CELL LINE, TUMOR; CHROMATIN; CLUSTER ANALYSIS; DISEASE PROGRESSION; DNA METHYLATION; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GENES, TUMOR SUPPRESSOR; HISTONES; HUMANS; IMMUNOPRECIPITATION; MALE; MICROARRAY ANALYSIS; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PHENOTYPE; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, NEOPLASM; URINARY BLADDER NEOPLASMS;

EID: 78651277534     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djq470     Document Type: Article

References (54)

1. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet. 2002;3(6):415-428.
2. Laird PW. Cancer epigenetics. Hum Mol Genet. 2005;14(Spec No 1): R65-R76.
3. Jones PA, Baylin SB. The epigenomics of cancer. Cell. 2007;128(4): 683-692.
4. Esteller M. Cancer epigenomics: DNA methylomes and histone-modifcation maps. Nat Rev Genet. 2007;8(4):286-298.
5. Gibbons RJ. Histone modifying and chromatin remodelling enzymes in cancer and dysplastic syndromes. Hum Mol Genet. 2005;14(Spec No 1): R85-R92.
6. Zaratiegui M, Irvine DV, Martienssen RA. Noncoding RNAs and gene silencing. Cell. 2007;128(4):763-776.
7. Yoo CB, Cheng JC, Jones PA. Zebularine: a new drug for epigenetic therapy. Biochem Soc Trans. 2004;32(pt 6):910-912.
8. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006;5(9):769-784.
9. Yoo CB, Jones PA. Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov. 2006;5(1):37-50.
10. Smith JS, Costello JF. A broad band of silence. Nat Genet. 2006;38(5): 504-506.
11. Stransky N, Vallot C, Reyal F, et al. Regional copy number-independent deregulation of transcription in cancer. Nat Genet. 2006;38(12): 1386-1396.
12. Novak P, Jensen T, Oshiro MM, et al. Epigenetic inactivation of the HOXA gene cluster in breast cancer. Cancer Res. 2006;66(22): 10664-10670.
13. Frigola J, Song J, Stirzaker C, Hinshelwood RA, Peinado MA, Clark SJ. Epigenetic remodeling in colorectal cancer results in coordinate gene suppression across an entire chromosome band. Nat Genet. 2006;38(5):540-549.
14. Coolen MW, Stirzaker C, Song JZ, et al. Consolidation of the cancer genome into domains of repressive chromatin by long-range epigenetic silencing (LRES) reduces transcriptional plasticity. Nat Cell Biol 2010;12(3):235-246.
15. Diez de Medina SG, Chopin D, El Marjou A, et al. Decreased expression of keratinocyte growth factor receptor in a subset of human transitional cell bladder carcinomas. Oncogene. 1997;14(3):323-330.
16. Sobin LH, Fleming ID. TNM Classifcation of Malignant Tumors, ffth edition (1997). Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer. 1997;80(9):1803-1804.
17. Mostof FK, Sobin LH, Torloni H. International Histological Classifcation of Tumors, No.10: Histological Typing of Urinary Bladder Tumors. Geneva, Switzerland: World Health Organization; 1973.
18. Chirgwin JM, Przybyla AE, MacDonald RJ, Rutter WJ. Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry. 1979;18(24):5294-5299.
19. Labarca C, Paigen K. A simple, rapid, and sensitive DNA assay procedure. Anal Biochem. 1980;102(2):344-352.
20. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA. 1998;95(25):14863-14868.
21. De Boer WI, Houtsmuller AB, Izadifar V, Muscatelli-Groux B, Van der Kwast TH, Chopin DK. Expression and functions of EGF, FGF and TGFbeta-growth-factor family members and their receptors in invasive human transitional-cell-carcinoma cells. Int J Cancer. 1997;71(2): 284-291.
22. Pinkel D, Segraves R, Sudar D, et al. High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays. Nat Genet. 1998;20(2):207-211.
23. Southgate J, Hutton KA, Thomas DF, Trejdosiewicz LK. Normal human urothelial cells in vitro: proliferation and induction of stratifcation. Lab Invest. 1994;71(4):583-594.
24. Southgate J, Masters JR, Trejdosiewicz LK. Culture of Human Urothelium. In: Freshney RI and Freshney MG, eds. Culture of Epithelial Cells. New York, NY: J Wiley and Sons. 2002;381-400.
25. Shen L, Kondo Y, Guo Y, et al. Genome-wide profling of DNA methyl-ation reveals a class of normally methylated CpG island promoters. PLoS Genet. 2007;3(10):2023-2036.
26. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25(4):402-408.
27. Xiong Z, Laird PW. COBRA: a sensitive and quantitative DNA methyla-tion assay. Nucleic Acids Res. 1997;25(12):2532-2534.
28. Van Oers JM, Lurkin I, Van Exsel AJ, et al. A simple and fast method for the simultaneous detection of nine fbroblast growth factor receptor 3 mutations in bladder cancer and voided urine. Clin Cancer Res. 2005; 11(21):7743-7748.
29. Wu XR. Urothelial tumorigenesis: a tale of divergent pathways. Nat Rev Cancer. 2005;5(9):713-725.
30. Billerey C, Chopin D, Aubriot-Lorton MH, et al. Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. Am J Pathol. 2001;158(6):1955-1959.
31. Dyrskjot L, Kruhoffer M, Thykjaer T, et al. Gene expression in the urinary bladder: a common carcinoma in situ gene expression signature exists disregarding histopathological classifcation. Cancer Res. 2004;64(11): 4040-4048.
32. Sylvester RJ, van der Meijden AP, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006;49(3):466-465. discussion 475-477.
33. Shih C, Weinberg RA. Isolation of a transforming sequence from a human bladder carcinoma cell line. Cell. 1982;29(1):161-169.
34. Jebar AH, Hurst CD, Tomlinson DC, Johnston C, Taylor CF, Knowles MA. FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma. Oncogene. 2005;24(33):5218-5225.
35. Zhang ZT, Pak J, Huang HY, et al. Role of Ha-ras activation in superfcial papillary pathway of urothelial tumor formation. Oncogene. 2001;20(16): 1973-1980.
36. Hitchins MP, Lin VA, Buckle A, et al. Epigenetic inactivation of a cluster of genes fanking MLH1 in microsatellite-unstable colorectal cancer. Cancer Res. 2007;67(19):9107-9116.
37. Novak P, Jensen T, Oshiro MM, Watts GS, Kim CJ, Futscher BW. Agglomerative epigenetic aberrations are a common event in human breast cancer. Cancer Res. 2008;68(20):8616-8625.
38. Carrel L, Willard HF. X-inactivation profle reveals extensive variability in X-linked gene expression in females. Nature. 2005;434(7031):400-404.
39. Heard E. Recent advances in X-chromosome inactivation. Curr Opin Cell Biol. 2004;16(3):247-255.
40. Li B, Carey M, Workman JL. The role of chromatin during transcription. Cell. 2007;128(4):707-719.
41. Fraser P, Bickmore W. Nuclear organization of the genome and the potential for gene regulation. Nature. 2007;447(7143):413-417.
42. Heard E, Bickmore W. The ins and outs of gene regulation and chromosome territory organisation. Curr Opin Cell Biol. 2007;19(3): 311-316.
43. Morey C, Da Silva NR, Perry P, Bickmore WA. Nuclear reorganisation and chromatin decondensation are conserved, but distinct, mechanisms linked to Hox gene activation. Development. 2007;134(5):909-919.
44. Spitz F, Gonzalez F, Duboule D. A global control region defnes a chromosomal regulatory landscape containing the HoxD cluster. Cell. 2003;113(3):405-417.
45. Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, Issa JP. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci USA. 1999;96(15):8681-8686.
46. Weisenberger DJ, Siegmund KD, Campan M, et al. CpG island methyl-ator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet. 2006; 38(7):787-793.
47. Shen L, Toyota M, Kondo Y, et al. Integrated genetic and epigenetic analysis identifes three different subclasses of colon cancer. Proc Natl Acad Sci USA. 2007;104(47):18654-18659.
48. Knowles MA. Molecular pathogenesis of bladder cancer. Int J Clin Oncol. 2008;13(4):287-297.
49. Bostwick DG, Montironi R, Qian J, Lopez-Beltran A, Cheng L. Urothelial bladder tumor pathology. In: Lerner SP, Schoenberg MP, Sternberg CN, eds. Textbook of Bladder Cancer. Abingdon, UK: Taylor & Francis; 2006.
50. Zieger K, Marcussen N, Borre M, Orntoft TF, Dyrskjot L. Consistent genomic alterations in carcinoma in situ of the urinary bladder confrm the presence of two major pathways in bladder cancer development. Int J Cancer. 2009;125(9):2095-2103.
51. Fu L, Qin YR, Xie D, et al. Characterization of a novel tumor-suppressor gene PLC delta 1 at 3p22 in esophageal squamous cell carcinoma. Cancer Res. 2007;67(22):10720-10726.
52. Ying J, Poon FF, Yu J, et al. DLEC1 is a functional 3p22.3 tumour suppressor silenced by promoter CpG methylation in colon and gastric cancers. Br J Cancer. 2009;100(4):663-669.
53. Chen H, Chung S, Sukumar S. HOXA5-induced apoptosis in breast cancer cells is mediated by caspases 2 and 8. Mol Cell Biol. 2004;24(2):924-935.
54. Rhoads K, Arderiu G, Charboneau A, Hansen SL, Hoffman W, Boudreau N. A role for Hox A5 in regulating angiogenesis and vascular patterning. Lymphat Res Biol. 2005;3(4):240-252.